uniQure(US:QURE) Globenewswire·2026-03-20 13:00Core Viewpoint - The Gross Law Firm is notifying shareholders of uniQure N.V. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Pivotal Study and Biologics License Application timeline [1][3]. Group 1: Allegations - The complaint alleges that during the class period from September 24, 2025, to October 31, 2025, uniQure's management issued materially false and/or misleading statements [3]. - It is claimed that the design of uniQure's Pivotal Study was not fully approved by the FDA, which was not disclosed to investors [3]. - The likelihood of a delay in the Biologics License Application timeline due to the need for additional studies was downplayed, leading to a lack of reasonable basis in the company's statements about its business and prospects [3]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action lawsuit by April 13, 2026, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].